Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical

Drug Profile

Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical

Alternative Names: Anti-FGF23 monoclonal antibody; Anti-fibroblast growth factor 23 monoclonal antibody; Burosumab; KRN-23; UX 023

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko Kirin
  • Developer Kyowa Hakko Kirin; Ultragenyx Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action Fibroblast growth factor 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - X-linked dominant hypophosphataemic rickets
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration X-linked dominant hypophosphataemic rickets
  • Phase II Nevus; Osteomalacia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in X-linked dominant hypophosphataemic rickets in USA (IV, Injection)
  • 02 Nov 2017 Updated efficacy data from a phase II trial in Osteomalacia released by Ultragenyx Pharmaceutical
  • 02 Nov 2017 Updated efficacy data from a phase III trial in X-linked dominant hypophosphataemic rickets released by Ultragenyx Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top